Results 71 to 80 of about 22,886 (216)

Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV

Fundamental &Clinical Pharmacology, Volume 39, Issue 4, August 2025.
ABSTRACT Background We aimed to elucidate the role of Angiotensin II type 1 receptor (AT1R) blocker usage in muscle wasting and dysfunction related to HIV. Research Design and Methods Appendicular skeletal muscle mass, higher and lower limb strength, and physical fitness were determined in people living with HIV (PWH) using AT1R blockers users (n = 33),
Rafael Deminice, Paola Sanches Cella, Ana Lúcia Borsari, Camila S. Padilha, Vitor Hugo Fernando de Oliveira   +4 more
wiley   +1 more source

Weight gain, obesity, and the impact of lifestyle factors among people living with HIV: A systematic review

Obesity Reviews, Volume 26, Issue 7, July 2025.
Summary HIV remains a significant health concern, but the advent of antiretroviral therapy (ART) has transformed it into a manageable chronic condition. However, weight gain and obesity pose a substantial challenge for people living with HIV (PLWH). Moreover, the role of lifestyle has not yet been comprehensively investigated.
Giulia Gilberti, Giorgio Tiecco, Silvia Marconi, Monica Marullo, Barbara Zanini, Eugenia Quiros‐Roldan   +5 more
wiley   +1 more source

Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.

PLoS ONE, 2019
BackgroundRoll-out of Integrase Strand Transfer Inhibitors (INSTIs) such as dolutegravir for HIV combination antiretroviral therapy (cART) in sub-Saharan Africa necessitates the development of affordable HIV drug resistance (HIVDR) assays targeting the ...
Kaelo K Seatla, Wonderful T Choga, Mompati Mogwele, Thabo Diphoko, Dorcas Maruapula, Lucy Mupfumi, Rosemary M Musonda, Christopher F Rowley, Ava Avalos, Ishmael Kasvosve, Sikhulile Moyo, Simani Gaseitsiwe   +11 more
doaj   +1 more source

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Viruses, 2015
Drug resistance prevents the successful treatment of HIV-positive individuals by decreasing viral sensitivity to a drug or a class of drugs. In addition to transmitted resistant viruses, treatment-naïve individuals can be confronted with the problem of ...
Thibault Mesplède, Mark A. Wainberg
doaj   +1 more source

The Complex Role of CD8+ T Cells in Placental HIV Infection

European Journal of Immunology, Volume 55, Issue 6, June 2025.
CD8+ T cells exhibit dual roles at the maternal‐fetal interface supporting tolerance via IL‐10 and TGF‐β and aiding implantation and vascular remodeling through TNF‐α and IFN‐γ. In HIV infection, CD8+ T cells expand, driving inflammation, PD‐L1 upregulation on trophoblasts, and cytotoxic dysfunction via reduced Granzyme B and Perforin, compromising ...
Kimberly Peta, Mushi Matjila, Nadia Ikumi   +2 more
wiley   +1 more source

HIV drug resistance, early treatment outcomes and impact of guidelines compliance after protease inhibitor‐based second‐line failure in a dedicated resistance clinic in western Kenya: a retrospective cohort study

Journal of the International AIDS Society, Volume 28, Issue 6, June 2025.
Abstract Introduction Data on drug resistance, viral outcomes and guidelines compliance following protease inhibitor (PI)‐based second‐line failure in low‐ and middle‐income countries are limited, particularly in the era of dolutegravir‐containing antiretroviral therapy (ART). Methods We conducted a retrospective cohort study of people living with HIV (
John M. Humphrey, Shamim M. Ali, Allison DeLong, Vlad Novitsky, Edwin Sang, Bilal Jawed, Emmanuel Kemboi, Celia Ngetich, Suzanne Goodrich, Adrian Gardner, Joseph W. Hogan, Rami Kantor   +11 more
wiley   +1 more source

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland

BMC Infectious Diseases, 2012
Background HIV integrase inhibitor use is limited by low genetic barrier to resistance and possible cross-resistance among representatives of this class of antiretrovirals.
Parczewski Miłosz, Bander Dorota, Urbańska Anna, Boroń-Kaczmarska Anna   +3 more
doaj   +1 more source

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies

HIV Medicine, Volume 26, Issue 6, Page 858-869, June 2025.
Abstract Introduction Black and Hispanic/Latine people are disproportionately affected by HIV‐1 and may have a greater risk of comorbidities than non‐Black and non‐Hispanic/Latine people with HIV. However, they have historically been underrepresented in HIV clinical studies.
C. Martorell, M. Ramgopal, D. Hagins, O. Osiyemi, J. R. Arribas, M. Berhe, Y. Yazdanpanah, C. Orkin, L. Santiago, C. Rosero, N. Unger, H. Liu, R. Rogers, J. T. Hindman, A. Wurapa   +14 more
wiley   +1 more source

Rethinking HIV treatment: How non‐integrase strand regimens may hold the key to better immune health

HIV Medicine, Volume 26, Issue 6, Page 879-887, June 2025.
Abstract Purpose HIV outcome changed drastically with antiretroviral (ARV) therapy, especially after the introduction of second‐generation integrase strand transfer inhibitors (INSTIs). Despite these advances, however, chronic immune activation and exhaustion, marked by programmed cell death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) upregulation ...
Bogusz Aksak‐Wąs, Karolina Skonieczna‐Żydecka, Miłosz Parczewski, Rafał Hrynkiewicz, Filip Lewandowski, Karol Serwin, Kaja Mielczak, Franciszek Lenkiewicz, Paulina Niedźwiedzka‐Rystwej   +8 more
wiley   +1 more source

Inhibition of lipid synthesis by the HIV integrase strand transfer inhibitor elvitegravir in primary rat oligodendrocyte cultures. [PDF]

Front Mol Neurosci, 2023
Monnerie H, Romer M, Roth LM, Long C, Millar JS, Jordan-Sciutto KL, Grinspan JB.   +6 more
europepmc   +1 more source